Artwork

内容由Hopkins Biotech Podcast提供。所有播客内容(包括剧集、图形和播客描述)均由 Hopkins Biotech Podcast 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

Robert Hollingsworth: The Future of iPSC-based Cell Therapy Technology

45:34
 
分享
 

Manage episode 342868736 series 2788785
内容由Hopkins Biotech Podcast提供。所有播客内容(包括剧集、图形和播客描述)均由 Hopkins Biotech Podcast 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Dr. Robert Hollingsworth is the current Chief Scientific Officer of Shoreline Biosciences, a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs)- utilizing its proprietary platforms. Dr. Hollingsworth joins Shoreline from Pfizer, where he served as Chief Scientific Officer and Vice President of Cancer Vaccines and Immunotherapeutics. Prior to Pfizer, he was Senior Director of Oncology Research at MedImmune where he led and advanced a large portfolio of more than twenty programs, including CAR-T programs, and contributed to the approval of durvalumab. Before that, he held several R&D positions at GSK, Pharmacia, and Upjohn.

In this episode, we discuss Robert’s long career in biopharma, the platform technology being developed at Shoreline, and the role of strategic partnerships in early-stage development.

Hosted by Gustavo Carrizo and Joe Varriale.

  continue reading

84集单集

Artwork
icon分享
 
Manage episode 342868736 series 2788785
内容由Hopkins Biotech Podcast提供。所有播客内容(包括剧集、图形和播客描述)均由 Hopkins Biotech Podcast 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Dr. Robert Hollingsworth is the current Chief Scientific Officer of Shoreline Biosciences, a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs)- utilizing its proprietary platforms. Dr. Hollingsworth joins Shoreline from Pfizer, where he served as Chief Scientific Officer and Vice President of Cancer Vaccines and Immunotherapeutics. Prior to Pfizer, he was Senior Director of Oncology Research at MedImmune where he led and advanced a large portfolio of more than twenty programs, including CAR-T programs, and contributed to the approval of durvalumab. Before that, he held several R&D positions at GSK, Pharmacia, and Upjohn.

In this episode, we discuss Robert’s long career in biopharma, the platform technology being developed at Shoreline, and the role of strategic partnerships in early-stage development.

Hosted by Gustavo Carrizo and Joe Varriale.

  continue reading

84集单集

所有剧集

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南

边探索边听这个节目
播放